Vision and Leadership
Collaboration and strong leadership make us a leading center for neurodegenerative research.
MassGeneral Institute for Neurodegenerative Disease (MIND) is committed to finding treatments and cures to improve the lives of patients with neurodegenerative disorders including Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s disease and Parkinson’s disease. Founded in 2001, MIND unites scientists and physician-scientists with the common goal of translating laboratory findings into the clinic where they can reach patients. Researchers in MIND laboratories work collaboratively to address important research questions and maximize synergy to yield the most promising results.
Many of the key findings in neurodegenerative disease are from MIND. SOD1, the most common mutation associated with ALS was identified at MIND. MIND researchers had a critical role in identifying every one of the Alzheimer’s disease genes that has been found except for ApoE. Additionally, the gene for Huntington’s disease, which has paved the way for greater understanding of the disease, was discovered at Mass General.
Members of industry are invited to join us in our commitment to translating science into the clinic. MIND strategically combines its scientific and clinical expertise with the resources of Massachusetts General Hospital, the Mass General Research Institute and the research and development resources of industry to generate tangible impacts.
Located in the heart of the biotech center of Boston, we can offer our collaborative partners:
- A vast research enterprise
- A full range of high tech core facilities
- A world-class staff of research scientists and clinicians
- In-house clinical research facilities
- Access to a variety of intellectual property
Partnerships between industry members and MIND provides benefits to both parties. Industry members get access to the latest healthcare challenges and research. They can work with our clinical and research teams to design and test hypothesis in one of the top research and clinical hospitals in the United States. For MIND researchers, the funding and support provided by industry helps to cover the gaps in funding that often occur during translational research. Researchers also gain access to industry experts who are experienced in developing products and bringing them to market.
To learn more about industry-researcher relationships at MIND, please visit Mass General Brigham Innovation.
Your contributions help drive discovery and propel findings from the laboratory bench into the clinic.